Certified Clinical Research Associate (CCRA) Practice Exam 2026 – Complete Preparation Guide

The correct answer is the report regarding patient recruitment strategies. Once an Investigational New Drug (IND) application becomes effective, the FDA requires several specific types of reports related to the clinical trial, such as safety monitoring, study progress, and information regarding the overall conduct of the trial.

Adverse event reports must be submitted to inform the FDA about any unexpected or serious adverse events that occur during the study. Annual reports are required to summarize the progress of clinical studies, including new safety information and updates on the overall trial conduct. Final reports are submitted at the end of the trial to provide comprehensive data on the outcomes and findings.

In contrast, patient recruitment strategies are not submitted to the FDA as a formal report. While the FDA is interested in the conduct of the trial and monitoring safety, specific recruitment strategies themselves are considered part of the operational and logistical aspects of how a clinical trial is run rather than a formal requirement for reporting. Therefore, this makes it the correct choice for the question regarding which report is NOT typically submitted to the FDA once an IND application is effective.